Products from BPS Bioscience require a minimum order value above 400€
Application: Use as negative control in the development of biologics targeting BCMA.Use as a control in CAR-T or NK co-culture killing assays.
Background: B-Cell Maturation Antigen (BCMA), also known as CD269, is a cell surface receptor of the TNF receptor superfamily that recognizes B-Cell Activating Factor (BAFF). BCMA is preferentially expressed on mature B-lymphocytes and Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy not only because of its restricted expression in nonmalignant tissue, but also due to its almost universal expression on MM cells. Pre-clinical studies using CAR (Chimeric Antigen Receptor) T cells targeting BCMA have demonstrated anti-MM activity, and in 2017, the FDA granted BCMA CAR-T Cell immunotherapy the breakthrough designation in treating Multiple Myeloma.
Description: BCMA Knockout RPMI-8226 Cell Line is an RPMI-8226 cell line in which BCMA (B-Cell Maturation Antigen, or CD269) has been genetically removed from RPMi-8226 cells using CRISPR/Cas9 genome editing by RNP (ribonucleoprotein) electroporation.This cell line has been validated by genome sequencing and flow cytometry.
Host Cell Line: RPMI-8226, human B cells isolated from a plasmacytoma/myeloma patient, suspension
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.
Supplied As: Each vial contains ˃1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-1
Deutsch
English
